Tulasi Atluri
About Tulasi Atluri
Tulasi Atluri is an Associate Director of Biospecimen Operations at Bolt Biotherapeutics, Inc., with a strong background in clinical research and biotechnology. Atluri has held various positions in the field, including roles at Quintiles, PharmaNet/i3, NHS Milton Keynes, and Bristol Myers Squibb.
Work at Bolt Biotherapeutics
Tulasi Atluri currently holds the position of Associate Director, Biospecimen Operations at Bolt Biotherapeutics, Inc. She has been with the company since 2021. In this role, she is responsible for overseeing biospecimen operations, ensuring that processes are efficient and compliant with regulatory standards. Her expertise contributes to the company's focus on developing innovative therapies.
Education and Expertise
Tulasi Atluri has a strong educational background in biotechnology and clinical research. She earned a Master's degree in Biotechnology from Bangalore University. Additionally, she studied Clinical Research at Cranfield University, where she achieved a Master of Science (MSc) from 2009 to 2010. She also obtained a certification in Biotechnology from the University of California, Santa Cruz, further enhancing her expertise in the field.
Background
Before joining Bolt Biotherapeutics, Tulasi Atluri gained diverse experience in the clinical research field. She worked as a Research Auditor at NHS Milton Keynes for four months in 2010. Following this, she served as a Researcher at ICRI Global in Milton Keynes for another four months. Her career continued at Quintiles as a Clinical Research Technician (CRT) for three months in 2011, and she later worked as a Clinical Data Processor/Analyst at PharmaNet/i3 Strategic Resourcing from 2011 to 2012.
Previous Roles at Bristol Myers Squibb
Tulasi Atluri worked at Bristol Myers Squibb as Associate Director, Biospecimen Planning Management, within the Biospecimen Operations team. Her tenure lasted for three months in 2020, during which she contributed to the management and planning of biospecimens, aligning with the company's research and development goals.